Insider Selling: Puma Biotechnology (NASDAQ:PBYI) Director Sells $121,500.00 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Michael Miller sold 15,000 shares of Puma Biotechnology stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $8.10, for a total transaction of $121,500.00. Following the completion of the sale, the director owned 66,000 shares in the company, valued at approximately $534,600. This represents a 18.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Puma Biotechnology Stock Performance

NASDAQ PBYI opened at $7.77 on Monday. Puma Biotechnology, Inc. has a 52 week low of $4.76 and a 52 week high of $11.50. The stock has a market cap of $401.71 million, a price-to-earnings ratio of 16.89 and a beta of 1.40. The company has a 50-day moving average price of $9.75 and a two-hundred day moving average price of $8.02.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. Puma Biotechnology had a return on equity of 17.50% and a net margin of 10.26%. The firm had revenue of $55.06 million for the quarter, compared to the consensus estimate of $57.50 million. As a group, equities research analysts expect that Puma Biotechnology, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on PBYI. Weiss Ratings cut shares of Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, November 10th. TD Cowen boosted their target price on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a report on Friday, August 7th. Finally, Wall Street Zen lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

View Our Latest Report on PBYI

Institutional Investors Weigh In On Puma Biotechnology

Several large investors have recently modified their holdings of PBYI. BlackRock Inc. purchased a new position in shares of Puma Biotechnology during the second quarter valued at $30,856,000. Globeflex Capital L P bought a new stake in Puma Biotechnology in the second quarter worth approximately $3,105,000. Wellington Management Group LLP acquired a new position in Puma Biotechnology during the second quarter worth $1,023,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Puma Biotechnology during the 2nd quarter valued at about $5,214,000. Finally, Bank of New York Mellon Corp acquired a new position in Puma Biotechnology during the second quarter valued at approximately $2,926,000. 61.29% of the stock is owned by institutional investors.

About Puma Biotechnology

(Get Free Report)

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing medicines for cancer treatment. Its work centers on targeted therapies, particularly treatments for breast cancer. The company’s principal product is Nerlynx (neratinib), an oral HER2-targeted medicine. In the United States, it is approved for certain patients with early-stage HER2-positive breast cancer following trastuzumab-based treatment, and for some patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine.

Featured Articles

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.